These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 31358938

  • 1. Distinct prognostic value of circulating anti-telomerase CD4+ Th1 immunity and exhausted PD-1+/TIM-3+ T cells in lung cancer.
    Laheurte C, Dosset M, Vernerey D, Boullerot L, Gaugler B, Gravelin E, Kaulek V, Jacquin M, Cuche L, Eberst G, Jacoulet P, Fabre E, Le Pimpec-Barthes F, Tartour E, De Carvalho Bittencourt M, Westeel V, Adotévi O.
    Br J Cancer; 2019 Aug; 121(5):405-416. PubMed ID: 31358938
    [Abstract] [Full Text] [Related]

  • 2. Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response.
    Godet Y, Fabre E, Dosset M, Lamuraglia M, Levionnois E, Ravel P, Benhamouda N, Cazes A, Le Pimpec-Barthes F, Gaugler B, Langlade-Demoyen P, Pivot X, Saas P, Maillère B, Tartour E, Borg C, Adotévi O.
    Clin Cancer Res; 2012 May 15; 18(10):2943-53. PubMed ID: 22407833
    [Abstract] [Full Text] [Related]

  • 3. Peripheral changes in immune cell populations and soluble mediators after anti-PD-1 therapy in non-small cell lung cancer and renal cell carcinoma patients.
    Juliá EP, Mandó P, Rizzo MM, Cueto GR, Tsou F, Luca R, Pupareli C, Bravo AI, Astorino W, Mordoh J, Martín C, Levy EM.
    Cancer Immunol Immunother; 2019 Oct 15; 68(10):1585-1596. PubMed ID: 31515670
    [Abstract] [Full Text] [Related]

  • 4. Cisplatin-based chemoradiation decreases telomerase-specific CD4 TH1 response but increases immune suppressive cells in peripheral blood.
    Boustani J, Joseph ELM, Martin E, Benhmida S, Lecoester B, Tochet F, Mirjolet C, Chevalier C, Thibouw D, Vulquin N, Servagi S, Sun X, Adotévi O.
    BMC Immunol; 2021 Jun 18; 22(1):38. PubMed ID: 34144673
    [Abstract] [Full Text] [Related]

  • 5. CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy.
    Kagamu H, Kitano S, Yamaguchi O, Yoshimura K, Horimoto K, Kitazawa M, Fukui K, Shiono A, Mouri A, Nishihara F, Miura Y, Hashimoto K, Murayama Y, Kaira K, Kobayashi K.
    Cancer Immunol Res; 2020 Mar 18; 8(3):334-344. PubMed ID: 31871122
    [Abstract] [Full Text] [Related]

  • 6. Naturally Occurring Telomerase-Specific CD4 T-Cell Immunity in Melanoma.
    Nardin C, Laheurte C, Puzenat E, Boullerot L, Ramseyer M, Marguier A, Jacquin M, Godet Y, Aubin F, Adotevi O.
    J Invest Dermatol; 2022 Feb 18; 142(2):435-444. PubMed ID: 34352265
    [Abstract] [Full Text] [Related]

  • 7. Increased exhausted CD8+ T cells with programmed death-1, T-cell immunoglobulin and mucin-domain-containing-3 phenotype in patients with multiple myeloma.
    Tan J, Chen S, Huang J, Chen Y, Yang L, Wang C, Zhong J, Lu Y, Wang L, Zhu K, Li Y.
    Asia Pac J Clin Oncol; 2018 Oct 18; 14(5):e266-e274. PubMed ID: 29943497
    [Abstract] [Full Text] [Related]

  • 8. Response to Chemoimmunotherapy Is Associated With Expansion of Systemic Antitumor CD4 + Th1 Response in Metastatic Non-Small Cell Lung Cancer.
    Wespiser M, Marguier A, Lecoester B, Richard T, Boullerot L, Malfroy M, Kumar A, Laheurte C, Adotévi O.
    J Immunother; 2023 Sep 01; 46(7):279-283. PubMed ID: 36799899
    [Abstract] [Full Text] [Related]

  • 9. [Up-regulation of TIM-3 on CD4+ tumor infiltrating lymphocytes predicts poor prognosis in human non-small-cell lung cancer].
    Ji P, Chen D, Bian J, Xia R, Song X, Wen W, Zhang X, Zhu Y.
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 Jun 01; 31(6):808-11. PubMed ID: 26062425
    [Abstract] [Full Text] [Related]

  • 10. Combinatorial Tim-3 and PD-1 activity sustains antigen-specific Th1 cell numbers during blood-stage malaria.
    Dookie RS, Villegas-Mendez A, Kroeze H, Barrett JR, Draper SJ, Franke-Fayard BM, Janse CJ, MacDonald AS, Couper KN.
    Parasite Immunol; 2020 Sep 01; 42(9):e12723. PubMed ID: 32306409
    [Abstract] [Full Text] [Related]

  • 11. Upregulation of bacterial-specific Th1 and Th17 responses that are enriched in CXCR5+CD4+ T cells in non-small cell lung cancer.
    Ma QY, Huang DY, Zhang HJ, Wang S, Chen XF.
    Int Immunopharmacol; 2017 Nov 01; 52():305-309. PubMed ID: 28982050
    [Abstract] [Full Text] [Related]

  • 12. Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer.
    Datta J, Berk E, Xu S, Fitzpatrick E, Rosemblit C, Lowenfeld L, Goodman N, Lewis DA, Zhang PJ, Fisher C, Roses RE, DeMichele A, Czerniecki BJ.
    Breast Cancer Res; 2015 May 23; 17(1):71. PubMed ID: 25997452
    [Abstract] [Full Text] [Related]

  • 13. TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression.
    Gao X, Zhu Y, Li G, Huang H, Zhang G, Wang F, Sun J, Yang Q, Zhang X, Lu B.
    PLoS One; 2012 May 23; 7(2):e30676. PubMed ID: 22363469
    [Abstract] [Full Text] [Related]

  • 14. 1α,25(OH)2D3 reverses exhaustion and enhances antitumor immunity of human cytotoxic T cells.
    Li P, Zhu X, Cao G, Wu R, Li K, Yuan W, Chen B, Sun G, Xia X, Zhang H, Wang X, Yin Z, Lu L, Gao Y.
    J Immunother Cancer; 2022 Mar 23; 10(3):. PubMed ID: 35318258
    [Abstract] [Full Text] [Related]

  • 15. Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumor.
    Dosset M, Godet Y, Vauchy C, Beziaud L, Lone YC, Sedlik C, Liard C, Levionnois E, Clerc B, Sandoval F, Daguindau E, Wain-Hobson S, Tartour E, Langlade-Demoyen P, Borg C, Adotévi O.
    Clin Cancer Res; 2012 Nov 15; 18(22):6284-95. PubMed ID: 23032748
    [Abstract] [Full Text] [Related]

  • 16. Advanced NSCLC patients with high IL-6 levels have altered peripheral T cell population and signaling.
    Rice SJ, Liu X, Zhang J, Jia B, Zheng H, Belani CP.
    Lung Cancer; 2019 May 15; 131():58-61. PubMed ID: 31027698
    [Abstract] [Full Text] [Related]

  • 17. Acute stimulation generates Tim-3-expressing T helper type 1 CD4 T cells that persist in vivo and show enhanced effector function.
    Gorman JV, Colgan JD.
    Immunology; 2018 Jul 15; 154(3):418-433. PubMed ID: 29315553
    [Abstract] [Full Text] [Related]

  • 18. Anti-Telomerase CD4+ Th1 Immunity and Monocytic-Myeloid-Derived-Suppressor Cells Are Associated with Long-Term Efficacy Achieved by Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) in Advanced Anal Squamous Cell Carcinoma: Translational Study of Epitopes-HPV01 and 02 Trials.
    Spehner L, Kim S, Vienot A, François E, Buecher B, Adotevi O, Vernerey D, Abdeljaoued S, Meurisse A, Borg C.
    Int J Mol Sci; 2020 Sep 17; 21(18):. PubMed ID: 32957741
    [Abstract] [Full Text] [Related]

  • 19. The distribution and function of human memory T cell subsets in lung cancer.
    Sheng SY, Gu Y, Lu CG, Zou JY, Hong H, Wang R.
    Immunol Res; 2017 Jun 17; 65(3):639-650. PubMed ID: 28101811
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.